Note to the businessman

Note to the businessman

How to make money on intellectual property?

On Amendments to Certain legislative acts of the Russian Federation on the creation of economic societies by budgetary scientific and educational institutions for the purpose of practical application (implementation) of the results of intellectual activity.

24.09.2009

Note to the businessman

Do you want to receive investments from Rosnanotech?

The procedure and formats of participation of Rosnanotech Group in nanotechnology investment funds determines the uniform conditions and procedure for participation of Rosnanotech Group in nanotechnology investment funds and the creation of such funds together with partners of Rosnanotech Group.

24.09.2009

Note to the businessman

Biotechnology a la francaise

France, being at the forefront of European countries in the field of biotechnology, has all the advantages to convince small and medium-sized enterprises engaged in biotechnology to make a choice towards their location on its territory.

17.09.2009

Note to the businessman

There is also a venture fund in Kuban – look through the microscope!

The shareholders of the project are a venture fund established by the regional administration and private investors. Priority areas are biotechnologies, pharmaceuticals, medical equipment, new materials, nanotechnology, alternative energy, energy engineering, IT technologies.

16.09.2009

Note to the businessman

Investors! Bring the money to Switzerland! But not to the bank :)

Switzerland provides significant benefits aimed at attracting investors and developing new industries, including the pharmaceutical industry, biotechnology, medical technology, micro- and nanotechnology.

16.09.2009

Note to the businessman

Pharmaceutical business and science

Journalists were impressed not so much by the hypothetically miraculous properties of the advertised drug, as by the emotional and patriotic history of the development of science in a commercial firm.

15.09.2009

Note to the businessman

Develop innovative medicines or promote existing ones?

With the onset of the economic downturn, the solution of this problem has become even more important for pharmaceutical companies, since it calls into question not only their financial success, but also their very physical existence.

31.08.2009

Note to the businessman

I'll buy a bankrupt pharmaceutical company. Bargaining is appropriate

Controlled by the senator from Tuva and the owner of the United Industrial Corporation Sergey Pugachev, OPK Biotech LLC acquired the American pharmaceutical company Biopure Corporation. The transaction amount is $4.9 million.

26.08.2009

Note to the businessman

Crisis and pharmaceutical production: slowing down underperformance

The first steps to stabilize the pharmaceutical market have already been taken: as a result of the efforts of pharmaceutical manufacturers, despite the crisis difficulties, the rate of decline in pharmaceutical production volumes observed since September 2008 has slowed down.

26.08.2009

Note to the businessman

Personalized medicine is the engine of progress

According to PricewaterhouseCoopers experts, a number of factors will contribute to the development of personalized medicine and increase the value of innovative diagnostic methods.

25.08.2009

Note to the businessman

Stem cells go to IPO: first-hand details

The projects of the Institute of Human Stem Cells are characterized by a quick return on investment, which will be visible in 1-2 years.

25.08.2009

Note to the businessman

The main problem of Russian science

The most important problem of Russian science now is not even low funding. The main problem is that our practical results are not in demand in our country either by the economy or by society.

22.07.2009

Note to the businessman

The tragedy of Russian pharmaceutical production: there is where, there is with whom, but with nothing…

The main problem of Russian pharmaceutical companies is not competition with Western colleagues, but inability to it. There are more than 600 different pharmaceutical companies operating in our country, but many of the drugs they produce are uncompetitive.

22.07.2009

Note to the businessman

Research institutes and universities were allowed to earn without the consent of the state

Yesterday, the Duma presented a draft Federal law "On Amendments to Certain Legislative Acts of the Russian Federation on the creation of economic societies by budgetary institutions of science and Education for the practical application (implementation) of the results of intellectual activity."

16.07.2009

Note to the businessman

Key indicators of Russian science in 2005-2007

Collection "Indicators of Science: 2009". The collection gives a very detailed picture of the state of Russian research and Development in recent years.

15.07.2009

Note to the businessman

MICEX will help innovative companies grow

The new MICEX sector is designed to bring, first of all, young high-tech companies to the market. High-tech companies, as well as those using bio- and nanotechnology, are prioritized.

10.07.2009

Note to the businessman

Do you need an IVAM nanospravochnik?

The IVAM Research Association has published the second edition of the best-selling Nano Guide of Europe, a database of more than 3,000 suppliers in the field of nanotechnology, microtechnology and modern materials.

07.07.2009

Note to the businessman

Innovation: all the secrets of Polichinel

Larry Wendling, Vice president of the 3M Research Laboratory, for the first time discovered the secret of how innovations have been created at his company for the second century.

06.07.2009

Note to the businessman

Festival of stupidity of subordinates

Every manager works with exactly the staff they deserve. Even more – any employee can become "stupid" with the appropriate quality of leadership work.

02.07.2009

Note to the businessman

There is no national science, just as there is no national multiplication table

Science has ceased to be national, says Dr. Ruth David, a member of the Presidential National Security Council of the United States, president of the independent non-profit research institute ANSER. According to her, the trend towards the globalization of science will lead to a gradual shift of research to developing countries.

18.06.2009